The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1385-1392

  Yerlikaya, Azmi ^a   Okur, Emrah ^a   Ulukaya, Engin ^b  

^a DUMLUPINAR UNIVERSITY   (Turkey)

^b ULUDAG UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Bortezomib; Cancer; Caspase; p53; Proteasome

Indexed keywords

BEVACIZUMAB; CASPASE 3; DNA; HEAT SHOCK PROTEIN 27; PROTEASOME; PROTEIN BAD; PROTEIN MCL 1; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; UBIQUITIN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVATION; NULL CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 84868091512     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0386-3     Document Type: Article

References (34)

1. Blank M, Shiloh Y. Programs for cell deathapoptosis is only one way to go. Cell Cycle. 2007;6(6):686-95.
2. Melino G, Knight RA, Nicotera P. How many ways to die? How many different models of cell death? Cell Death Differ. 2005;12:1457-62.
3. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239-57.
4. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosisthe p53 network. J Cell Sci. 2003;116(20):4077-85.
5. Lopes UG, Erhardt P, Yao R, Cooper GM. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem. 1997;272(20):12893-6.
6. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 1996;56(11):2649-54.
7. Saito A, Hayashi T, Okuno S, Nishi T, Chan PH. Modulation of p53 degradation via MDM2-mediated ubiquitylation and the ubiquitin-proteasome system during reperfusion after stroke: role of oxidative stress. J Cereb Blood Flow Metab. 2005;25(2):267-80.
8. Urist M, Tanaka T, Poyurovsky MV, Prives C. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev. 2004;18(24):3041-54.
9. Rieber MS, Zangemeister-Wittke U, Rieber M. P53-independent induction of apoptosis in human melanoma cells by a bcl-2/bcl-xL bispecific antisense oligonucleotide. Clin Cancer Res. 2001;7(5):1446-51.
10. Fricker M, Papadia S, Hardingham GE, Tolkovsky AM. Implication of TAp73 in the p53-independent pathway of Puma induction and Puma-dependent apoptosis in primary cortical neurons. J Neurochem. 2010;114(3):772-83.
11. Jullig M, Zhang WV, Ferreira A, Stott NS. MG132 induced apoptosis is associated with p53-independent induction of pro-apoptotic Noxa and transcriptional activity of beta-catenin. Apoptosis. 2006;11(4):627-41.
12. Kim SG, Ravi G, Hoffmann C, Jung YJ, Kim M, Chen A, et al. p53-Independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, Cl-IB-MECA. Biochem Pharmacol. 2002;63(5):871-80.
13. Seol DW. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun. 2011;416(1-2):222-5.
14. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol. 2001; chapter 20: unit 20.2.
15. Erin N, Akdas Barkan G, Harms JF, Clawson GA. Vagotomy enhances experimental metastases of 4THMpc breast cancer cells and alters substance P level. Regul Pept. 2008;151(1-3):35-42.
16. Glinsky GV, Glinsky VV, Ivanova AB, Hueser CJ. Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett. 1997;115(2):185-93.
17. Yerlikaya A, Erin N. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade. Intl J Mol Med. 2008;22(6):817-23.
18. Pantazis P, Early JA, Mendoza JT, DeJesus AR, Giovanella BC. Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro. Cancer Res. 1994;54(3):771-6.
19. Zou P, Kawada J, Pesnicak L, Cohen JI. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J Virol. 2007;81(18):10029-36.
20. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol. 2004;54(4):343-53.
21. MacLaren AP, Chapman RS, Wyllie AH, Watson CJ. p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ. 2001;8(3):210-8.
22. Lanni JS, Lowe SW, Licitra EJ, Liu JO, Jacks T. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci USA. 1997;94(18):9679-83.
23. McNamee LM, Brodsky MH. p53-Independent apoptosis limits DNA damage-Induced aneuploidy. Genetics. 2009;182(2):423-35.
24. Pandit B, Gartel AL. Proteasome inhibitors induce p53-independent apoptosis in human cancer cells. Am J Pathol. 2011;178(1):355-60.
25. An WG, Hwang SG, Trepel JB, Blagosklonny MV. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia. 2000;14(7):1276-83.
26. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006;107(1):257-64.
27. Ri M, Iida S, Ishida T, Ito A, Yano H, Inagaki A, et al. Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1. Cancer Sci. 2009;100(2):341-8.
28. Rizzatti EG, Mora-Jensen H, Weniger MA, Gibellini F, Lee E, Daibata M, et al. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways. Leuk Lymphoma. 2008;49(4):798-808.
29. Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, et al. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro. Invest Ophthalmol Vis Sci. 2007;48(10):4706-19.
30. Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene 2008; S71-83.
31. Combaret V, Boyault S, Iacono I, Brejon S, Rousseau R, Puisieux A. Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. Mol Cancer. 2008;7:50.
32. Nencioni A, Hua F, Dillon CP, Yokoo R, Scheiermann C, Cardone MH, et al. Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood. 2005;105(8):3255-62.
33. Awasthi N, Wagner BJ. Upregulation of heat shock protein expression by proteasome inhibition: an antiapoptotic mechanism in the lens. Invest Ophthalmol Vis Sci. 2005;46(6):2082-91.
34. Bruey JM, Ducasse C, Bonniaud P, Ravagnan L, Susin SA, Diaz-Latoud C, et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol. 2000;2(9):645-52.